Thus, based on the observations reported previously, it is predictable that exogenous modulation of BCL-X AS through administration of ASOs, or by interfering with the activity of the splicing factors that promote the anti-apoptotic BCL-XL variant, will enhance the efficacy of chemotherapy in advanced PCa, as suggested by preclinical studies in PCa cell lines [30, 31, 45]. This evidence concerns the gene BCL2L1 and posterior cortical atrophy.